Search clinical trials for: MK-3475

Total 1874 results

Urovant Sciences GmbH

Completed

An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB). (Empowur)

Overactive Bladder

United States
Merck Sharp & Dohme LLC

Completed

Efficacy, Safety and Pharmacokinetics of Sugammadex (Org 25969; MK-8616) at 3 Different Time Points After 0.6 mg/kg Esmeron® in Male Participants (P05940; MK-8616-020).

Neuromuscular Blockade
Merck Sharp & Dohme LLC

Completed

MK-0954E Study in Participants With Hypertension (MK-0954E-357)

Hypertension
University of Ioannina
University of Patras; Tottori University Hospital

Completed

GnRH-a and Pregnancy Rate in In Vitro Fertilization (IVF) Cycles.

Infertility | Endometriosis

Greece
L. Nicolas Gonzalez Castro, MD, PhD
Merck Sharp & Dohme LLC

Recruiting

Surgical Pembro +/- Olaparib w TMZ for rGBM

Glioblastoma | Recurrent Glioblastoma

United States
Germans Trias i Pujol Hospital
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la...

Completed

Impact of MK-0518 (Raltegravir) Intensification on HIV-1 Viral Latency in Patients With Previous Complete Viral Suppression

HIV Infections

Spain
Merck Sharp & Dohme LLC

Terminated

A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)

Hypercholesterolemia, Familial | Heterozygous Familial Hypercholesterolemia
Indiana University
Vanderbilt University

Terminated

Nitroglycerin vs. Furosemide Using Lung Ultrasound Pilot Trial (N-FURIOUS)

Heart Failure | Acute Cardiac Failure | Acute Cardiac Pulmonary Edema | Heart Failure Acute

United States
University of Michigan Rogel Cancer Center

Completed

Dose Escalation Trial of AZD1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas

Adenocarcinoma of the Pancreas

United States
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Sugammadex (Org 25969, MK-8616) in Participants With or Having a Past History of Pulmonary Disease (19.4.308) (P05932) (MK-8616-017)

Anesthesia, General
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)

Glioblastoma | Malignant Glioma | Gliosarcoma

United States
Dana-Farber Cancer Institute
Genentech, Inc.; Biogen

Completed

Rituximab for Prevention of Chronic GVHD

Hematological Malignancies

United States
Tharick Pascoal
National Institute on Aging (NIA)

Recruiting

Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease (HEAD)

Alzheimer Disease

United States, Canada, Spain
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Metastatic Malignant Neoplasm in the Brain and other conditions

United States
Fundación FLS de Lucha Contra el Sida, las Enfermedades...
Institut d'Investigació Biomèdica de Bellvitge; Hospital Universitari de Bellvitge

Completed

Doravirine Concentrations and Antiviral Activity in Cerebrospinal Fluid in HIV-1 Infected Individuals

HIV-1-infection

Spain
Merck Sharp & Dohme LLC

Completed

A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013)

Gram-Positive Bacterial Infections
University Hospital, Toulouse

Completed

Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab (PK-rituximab)

Autoimmune Diseases | Renal Transplant

France
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Suvorexant (MK-4305) for Reducing Incidence of Delirium in Japanese Participants at High Risk of Delirium (MK-4305-085)

Delirium

Japan
Organon and Co

Completed

Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05693 (P05713) (Care)

Pregnancy | Neonates
Merck Sharp & Dohme LLC

Completed

Effects of Doravirine (MK-1439) on Methadone Pharmacokinetics in Methadone-Maintained Participants (MK-1439-045)

Human Immunodeficiency Virus (HIV) Infection
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1)

Sarcoma
Merck Sharp & Dohme LLC

Completed

Islatravir and Methadone Pharmacokinetics (MK-8591-029)

HIV-1 Infection

United States
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics of Ridaforolimus (MK-8669) in Chinese Participants (MK-8669-059)

Cancer, Advanced
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Withdrawn

Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)

Prostate Cancer

United States
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)

Lymphoma | Multiple Myeloma | Tumors
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)

Lymphoma | Myelodysplastic Syndromes | Leukemia | Hematologic Malignancies | Myeloid Metaplasia

United States
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED)

Cancer
Ono Pharmaceutical Co. Ltd

Completed

MK-0431/ONO-5435 Phase III Clinical Trial - Insulin Add-on Study for Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Maastricht University

Completed

Safety Study of Vitamin K2 During Anticoagulation in Human Volunteers

Healthy

Netherlands
University of Washington
National Cancer Institute (NCI); Syntrix Biosystems, Inc.

Recruiting

SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
National Cancer Institute (NCI)

Suspended

A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy in Patients With Operable Melanoma

Clinical Stage III Cutaneous Melanoma AJCC v8 | Melanoma of Unknown Primary | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Recurrent Cutaneous Melanoma

United States
Eli Lilly and Company
ARMO BioSciences

Active, not recruiting

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors (IVY)

Melanoma | Renal Cell Carcinoma | Breast Cancer | Ovarian Cancer | Prostate Cancer | Non-small Cell Lung Carcinoma | Solid Tumors | Colorectal Carcinoma | Pancreatic Carcinoma

United States
Mayo Clinic

Recruiting

A Study of FRaDCs for Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Ovarian High Grade Serous Adenocarcinoma | Fallopian Tube Carcinosarcoma | Primary Peritoneal Carcinosarcoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian... and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Biomarkers to Classify Young Patients With Acute Lymphoblastic Leukemia (ALL) and Remission Induction Therapy in Young Patients With B-Precursor ALL

Leukemia
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy

Leukemia

United States, Canada, Australia, Puerto Rico, Switzerland
Merck Sharp & Dohme LLC

Completed

MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042)

Cytomegalovirus Infection | Cytomegalovirus Disease

Japan
Merck Sharp & Dohme LLC

Completed

Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (MK-8228-030)

Cytomegalovirus (CMV) Infection

United States, Australia, Colombia, France, Germany, Israel, Japan, Mexico, Poland, Spain, Turkey
Fundación FLS de Lucha Contra el Sida, las Enfermedades...
Institut d'Investigació Biomèdica de Bellvitge; Hospital Universitari de Bellvitge

Completed

Doravirine Concentrations and Antiviral Activity in Genital Fluids in HIV-1 Infected Individuals

HIV-1-infection

Spain
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Alzheimer's Disease (MK-4305-061)

Sleep Initiation and Maintenance Disorders | Alzheimer Disease
Merck Sharp & Dohme LLC

Completed

A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)

Urinary Bladder, Overactive
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics of Suvorexant in Participants With Impaired Renal Function (MK-4305-023)(COMPLETED)

Insomnia
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics of Suvorexant in Participants With Hepatic Insufficiency (MK-4305-017)

Hepatic Insufficiency | Insomnia
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003)

Type 1 Diabetes Mellitus
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)

Lymphoma | Multiple Myeloma | Tumors

United States
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED)

Endometrial Cancer
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

TTI-622 and TTI-621 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Recurrent Diffuse Large B-Cell... and other conditions

United States
University of Southern California
National Cancer Institute (NCI)

Recruiting

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Advanced Malignant Skin Neoplasm | Metastatic Malignant Skin Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Suspended

Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma

Glioblastoma | Gliosarcoma | Supratentorial Glioblastoma

United States
Naurex, Inc, an affiliate of Allergan plc

Completed

Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers (NRX-1074)

Major Depressive Disorder

United States

Search clinical trials for: MK-3475

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations